Synthesis of 2-arylfuro[3,2-b]pyridines: Effect of the C2-aryl group on melatoninergic activity

European Journal of Medicinal Chemistry

Volumn 109, Issue , 2016, Pages 268-275

  Couhert, Audrey ^a   Delagrange, Philippe ^b   Caignard, Daniel Henri ^b   Chartier, Agnès ^a   Suzenet, Franck ^a   Guillaumet, Gérald ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Furopyridine; Melatonin receptors; Melatoninergic activity; SAR

Indexed keywords

2 ARYLFURO[3,2 B ]PYRIDINE DERIVATIVE; LIGAND; MELATONIN RECEPTOR; N [2 (5 METHOXY 2 PHENYLFURO [3,2B] PYRIDIN 3 YL)ETHYL]ACETAMIDE; N [2 [2 (2,6 DIMETHYLPHENYL) 5 METHOXYFURO[3,2B] PYRIDIN 3 YL]ETHYL]ACETAMIDE; N [2 [2 (4 FLUOROPHENYL)5 METHOXYFURO[3,2B] PYRIDIN 3 YL]ETHYL]ACETAMIDE; N [2 [2 (ANTHRACEN 9 YL) 5 METHOXYFURO[3,2B] PYRIDIN 3 YL]ETHYL]ACETAMIDE; N [2 [5 METHOXY 2 (NAPHTHALEN 1 YL)FURO[3,2 B]PYRIDIN 3YL]ETHYL]ACETAMIDE; N [2 [5 METHOXY 2 (NAPHTHALEN 2 YL)FURO[3,2B] PYRIDIN 3 YL]ETHYL]ACETAMIDE; N [2 [5 METHOXY 2 (PHENANTHREN 9 YL)FURO[3,2B] PYRIDIN 3 YL]ETHYL]ACETAMIDE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NAPHTHALENE DERIVATIVE; PROTEIN BINDING;

ARTICLE; CONFORMATION; DRUG SYNTHESIS; STEREOSPECIFICITY; SUZUKI REACTION; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; HEK293 CELL LINE; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; CHO CELLS; CRICETULUS; HEK293 CELLS; HUMANS; NAPHTHALENES; PROTEIN BINDING; PYRIDINES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84954284931     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.01.008     Document Type: Article

References (41)

1. F.A.J.L. Scheer, and C.A. Czeisler Melatonin, sleep, and circadian rhythms Sleep Med. Rev. 9 2005 5 9
2. A. Carrillo-Vico, J.M. Guerrero, P.J. Lardone, and R.J. Reiter A review of the multiple actions of melatonin on the immune system Endocrine 27 2005 189 200
3. T. Frese, A.G. Bach, E. Mühlbauer, K. Pönicke, H.-J. Brömme, A. Welp, and E. Peschke Pineal melatonin synthesis is decreased in type 2 diabetic Goto-Kakizaki rats Life Sci. 85 2009 526 533
4. E. Fertl, A. Doppelbauer, and F. Waldhauser Circadian secretion pattern of melatonin in Parkinson's disease J. Neural Trans. 3 1991 41 47
5. X.-T. Luo, C.-M. Wang, Y. Liu, and Z.-G. Huang New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease Eur. J. Med. Chem. 103 2015 302 311
6. E. Esposito, and S. Cuzzocrea Antiinflammatory activity of melatonin in central nervous system Curr. Neuropharmacol. 8 2010 228 242
7. M. Ambriz-Tututi, H.I. Rocha-Gonzalez, S.L. Cruz, and V. Granados-Soto Melatonin: a hormone that modulates pain Life Sci. 84 2009 489 498
8. R. Hardeland Antioxidative protection by melatonin Endocrine 27 2005 119 130
9. R. Mogulkoc, A.K. Baltaci, E. Oztekin, L. Aydin, and A. Sivrikaya Melatonin prevents oxidant damage in various tissues of rats with hyperthyroidism Life Sci. 79 2006 311 315
10. P.M. Iuvone, G. Tosini, N. Pozdeyev, H. Rashidul, D.C. Klein, and S.S. Chaurasia Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina Prog. Retin. Eye Res. 24 2005 433 456
11. E. Sewerynek Melatonin and the cardiovascular system, Neuro Endocrinol. Lett. 23 2002 79 83
12. D.E. Blask Melatonin, sleep disturbance and cancer risk Sleep Med. Rev. 13 2009 257 264
13. D.P. Cardinali, and P. Pévet Basic aspects of melatonin action Sleep Med. Rev. 2 1998 175 190
14. N. Shimizu, K. Sugimoto, M. Nozawa, Y. Kobayashi, Y. Yamamoto, T. Minami, T. Hayashi, K. Yoshimura, T. Ishii, H. Uemura, K. Nose, and T. Nishioka Efficacy of Ramelteon in patients with insomnia and nocturia LUTS 5 2013 69 74
15. C. De Bodinat, B. Guardiola-Lemaitre, E. Mocaër, P. Renard, C. Muñoz, and M.J. Milan Agomelatine, the first melatonergic antidepressant: discovery, characterization and development Nat. Rev. Drug Discov. 9 2010 628 642
16. 2C receptor subtypes Eur. J. Med. Chem. 90 2015 822 833
17. P.A. Witt-Enderby, J. Bennett, M.J. Jarzynka, S. Firestine, and M.A. Melan Melatonin receptors and their regulation: biochemical and structural mechanisms Life Sci. 72 2003 2183 2198
18. C. Ekmekcioglu Melatonin receptors in humans: biological role and clinical relevance Biomed. Pharmacother. 60 2006 97 108
19. 2 melatonin receptors: ligands, models, oligomers, and therapeutic potential J. Med. Chem. 57 2014 3161 3185
20. 2-selective melatonin receptor antagonist Med. Chem. Comm. 2 2011 991 994
21. 2-selective melatonin ligands Bioorg. Med. Chem. Lett. 20 2010 2582 2585
22. 2 melatoninergic ligands Bioorg. Med. Chem. 11 2003 753 759
23. 2-selective melatonin receptor ligands J. Med. Chem. 49 2006 7393 7403
24. 2-selective agonists J. Med. Chem. 54 2011 3436 3444
25. 2 receptor ligands Eur. J. Med. Chem. 46 2011 1835 1840
26. Y. Hu, J. Zhu, K.H. Chan, and Y.H. Wong Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability Bioorg. Med. Chem. 21 2013 547 552
27. M. Mor, G. Spadoni, B. Di Giacomo, G. Diamantini, A. Bedini, G. Tarzia, P.V. Plazzi, S. Rivara, R. Nonno, V. Lucini, M. Pannacci, F. Fraschini, and B.M. Stankov Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands Bioorg. Med. Chem. 9 2001 1045 1057
28. 2 Selective melatonin receptor antagonists: design and structure-activity relationships Arkivoc 8 2006 8 16
29. 2-selective melatonin receptor antagonists J. Med. Chem. 52 2009 826 833
30. 2 melatonin receptor selective ligands J. Med. Chem. 45 2002 2788 2800
31. H. Van de Poël Synthèse et propriétés pharmacologiques de ligands mélatoninergiques à structure furo- et pyrrolopyridinique (PhD thesis) 2000 Orleans University
32. H. Van de Poël, G. Guillaumet, and M.-C. Viaud-Massuard Synthesis of melatonin analogues derived from furo[2,3-b]- and [2,3-c]pyridines by use of a palladium-copper catalyst system Heterocycles 57 2002 55 71
33. S. El Kazzouli, A. Griffon du Bellay, S. Berteina-Raboin, P. Delagrange, D.-H. Caignard, and G. Guillaumet Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands Eur. J. Med. Chem. 45 2011 4252 4257
34. 2 melatonin receptors Int. J. Mol. Sci. 14 2013 8948 8962
35. K. Green Improved metalation of 2,4,6-tribromoanisole: synthesis of 2-methoxyresorcinol J. Org. Chem. 56 1991 4325 4326
36. J. Martel, P. Girault, Patent FR2498421 (29-01-1981). Chem. Abst.: 1982:610477
37. Y. Hajbi, C. Neagoie, B. Biannic, A. Chilloux, E. Vedrenne, B. Baldeyrou, C. Bailly, J.-Y. Mérour, S. Rosca, S. Routier, and A. Lansiaux Synthesis and biological activities of new furo[3,4-b]carbazoles: potential topoisomerase II inhibitors Eur. J. Med. Chem. 45 2010 5428 5437
38. A. Jasselin-Hinschberger, C. Comoy, A. Chartoire, and Y. Fort Successive regioselective metalations of fused heterocycles: synthesis of polyfunctionalized furo[3,2-b]pyridines J. Org. Chem. 78 2013 5618 5626
39. 2 receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 367 2003 553 561
40. 2-selective melatonin receptor antagonists J. Med. Chem. 52 2009 826 833
41. P. Paul, C. Lahaye, P. Delagrange, J.P. Nicolas, E. Canet, and J.A. Boutin Characterization of 2-[125I]iodomelatonin binding sites in syrian hamster peripheral organs J. Pharmacol. Exp. Ther. 290 1999 334 340